Doctor profile · Federal record

Dr. Walid El Ayass, M.D

Hematology & Oncology Physician (CMS: Hematology/Oncology) · Salisbury, MD

  • NPI 1700078250
  • Accepts Medicare
  • MIPS 79.5 / 100 · 2023
  • 21 yrs in practice
  • Male
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
100 E Carroll Street
Salisbury, MD 218015422
(410) 749-1282
fax (410) 749-7821

Credentials & registration

NPPES · NUCC
NPI registered
August 2007 — 19 yrs on file
Profile last updated
April 24, 2014
Year of graduation
2005 — 21 yrs since
Specialty taxonomy
207RH0003X — NUCC code
State license (1)
Maryland #D73895

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1700078250. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
15,170
Distinct HCPCS
10
Medicare allowed
$598,426
HCPCS Description Services Patients Avg allowed
J2357 Injection, omalizumab, 5 mg 4,815 20 $38
J2182 Injection, mepolizumab, 1 mg 4,700 13 $29
J0897 Injection, denosumab, 1 mg 4,020 19 $23
99214 Established patient office or other outpatient visit, 30-39 minutes 266 131 $126
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle 262 61 $79
99213 Established patient office or other outpatient visit, 20-29 minutes 198 151 $84
99214 Established patient office or other outpatient visit, 30-39 minutes 189 92 $101
99215 Established patient office or other outpatient visit, 40-54 minutes 142 46 $149
99215 Established patient office or other outpatient visit, 40-54 minutes 122 45 $172
96413 Administration of chemotherapy into vein, 1 hour or less 76 33 $134

In context: peer comparison

Among 3 peers in Salisbury Hematology & Oncology Physician, average services per provider: 460. This provider delivers 33× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$46,643
Transactions
87
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Lilly USA, LLC 35 $30,341.70
AstraZeneca Pharmaceuticals Lp 15 $13,005.91
Novartis Pharmaceuticals Corporation 4 $2,000.28
Janssen Biotech, INC. 3 $200.49
Daiichi Sankyo INC. 9 $198.01
Eisai INC. 3 $154.46
GlaxoSmithKline, LLC. 5 $133.79
BeiGene USA, INC. 1 $120.83
Puma Biotechnology, INC. 1 $111.35
Pfizer INC. 3 $83.81
Gilead Sciences, INC. 3 $73.74
Genentech USA, INC. 2 $50.38
Regeneron Healthcare Solutions, INC. 1 $38.39
Alexion Pharmaceuticals, INC. 1 $30.65
Astellas Pharma US INC 1 $29.48

By nature of payment

Compensation for Services Other Than Consulting, Including Serving As Faculty or As A Speaker at A Venue Other Than A Continuing Education Program
$38,606
Travel and Lodging
$3,888
Food and Beverage
$2,285
Consulting Fee
$1,838
Education
$26

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
782
Patients
239
Total drug cost
$34,943
Drug Type Claims Patients Total cost
Letrozole Generic 389 105 $8,118
Tamoxifen Citrate Generic 153 45 $4,331
Anastrozole Generic 43 18 $1,561
Potassium Chloride Generic 39 11 $556
Exemestane Generic 37 16 $13,661
Enoxaparin Sodium Generic 25 0 $5,474
Gabapentin Generic 24 0 $79
Lidocaine-Prilocaine (Lidocaine/Prilocaine) Brand 23 15 $410
Prochlorperazine Maleate Generic 21 16 $397
Ondansetron Hcl Generic 17 13 $228

Frequently asked questions

Auto-generated from federal data
What is Dr. Walid El Ayass's medical specialty?
Dr. Walid El Ayass practices Hematology & Oncology Physician in Salisbury, MD.
Where does Dr. Walid El Ayass practice?
Dr. Walid El Ayass practices at 100 E Carroll Street, Salisbury, MD 218015422. Office phone: 4107491282.
What is Dr. Walid El Ayass's NPI?
Dr. Walid El Ayass's National Provider Identifier (NPI) is 1700078250, issued by NPPES.
Does Dr. Walid El Ayass accept Medicare assignment?
Yes. Dr. Walid El Ayass accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Walid El Ayass commonly perform?
Top Medicare-reported procedures in 2023: Injection, omalizumab, 5 mg (HCPCS J2357); Injection, mepolizumab, 1 mg (HCPCS J2182); Injection, denosumab, 1 mg (HCPCS J0897). Source: CMS Medicare Physician & Other Practitioners file.